Inhibiteurs des Janus kinases : nouvelles perspectives pour la médecine de précision ? [Janus kinase inhibitors : new perspectives for precision medicine ?]
Fiche du document
19 octobre 2022
- doi: 10.53738/REVMED.2022.18.800.1979
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.800.1979
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36259705
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0D12F79D0C495
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-04-18 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Legends and stories Novels Stories Printing, Offset Lithoprinting Impresión offset EC 2.7 Phosphoryl-transférases Kinases Catalyse négative Inhibiteurs chimiques Inhibition (chimie) Impression offset Impression-transfert Procédé offset Rotocalcographie Nouvelles (littérature) RécitsCiter ce document
J. Tachet et al., « Inhibiteurs des Janus kinases : nouvelles perspectives pour la médecine de précision ? [Janus kinase inhibitors : new perspectives for precision medicine ?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.800.1979
Métriques
Partage / Export
Résumé
Janus kinase inhibitors (JAKi), such as tofacitinib, baricitinib, upadacitinib or ruxolitinib, are small molecules active on specific intracellular targets and used orally for the treatment of autoimmune or myeloproliferative diseases. Their remarkable therapeutic efficacy is offset by a significant risk of toxicities, essentially dose-dependent and a variable pharmacokinetic profile. The JAKi represent a new therapeutic armamentarium for treating autoimmune, myeloproliferative and inflammatory diseases (incl. COVID-19), but require thorough treatment individualization and close monitoring. Therapeutic Drug Monitoring (TDM) of JAKi could allow a personalized prescription and improve the efficacy-toxicity profile.